Literature DB >> 10430507

Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin.

R Stanislaus1, K Pahan, A K Singh, I Singh.   

Abstract

Proinflammatory cytokines and inducible nitric oxide synthase (iNOS) are involved in the pathogenesis of experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). We have previously reported that lovastatin (Pahan, K., Sheikh., F.G., Namboodiri, A. and Singh, I., Lovastatin and Phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia and macrophages. J. Clin. Invest., 100 (1997) 2671-2679.), an inhibitor of the mevalonate pathway, inhibits the expression of iNOS and proinflammatory cytokines in rat primary glial cells (astroglia and microglia) and macrophages. The present study underlines the therapeutic importance of lovastatin in ameliorating the neuroinflammatory disease process in the central nervous system of EAE rats. Immunohistochemical results show a higher degree of expression of iNOS, tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) in brains of rats with acute monophasic EAE relative to the control animals. Administration of lovastatin inhibited the expression of iNOS, TNF-alpha and IFN-gamma in the CNS of EAE rats and improved the clinical signs of EAE suggesting that this compound may have therapeutic potential in the treatment of neuroinflammatory diseases like MS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430507     DOI: 10.1016/s0304-3940(99)00414-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  37 in total

Review 1.  Statins for multiple sclerosis.

Authors:  Jin Wang; Yousheng Xiao; Man Luo; Hongye Luo
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 2.  Statin therapy and autoimmune disease: from protein prenylation to immunomodulation.

Authors:  John Greenwood; Lawrence Steinman; Scott S Zamvil
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

Review 3.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 4.  Statins as potential therapeutic agents in multiple sclerosis.

Authors:  Olaf Stüve; Thomas Prod'homme; Sawsan Youssef; Shannon Dunn; Oliver Neuhaus; Martin Weber; Hans-Peter Hartung; Lawrence Steinman; Scott S Zamvil
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

Review 5.  Exercise and brain health--implications for multiple sclerosis: Part II--immune factors and stress hormones.

Authors:  Lesley J White; Vanessa Castellano
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

Review 6.  Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations.

Authors:  Eilhard Mix; Hans Meyer-Rienecker; Uwe K Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

7.  Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice.

Authors:  James A Carroll; Brent Race; Katie Phillips; James F Striebel; Bruce Chesebro
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

Review 8.  [Statins for treatment of CNS diseases. Status report from research and clinical practice].

Authors:  T Menge; H-C von Büdingen; S S Zamvil; H-P Hartung; B C Kieseier; O Stüve
Journal:  Nervenarzt       Date:  2005-04       Impact factor: 1.214

9.  Simvastatin protects bladder and renal functions following spinal cord injury in rats.

Authors:  Anandakumar Shunmugavel; Mushfiquddin Khan; Peter C Te Chou; Ramanpreet K Dhindsa; Marcus M Martin; Anne G Copay; Brian R Subach; Thomas C Schuler; Mehmet Bilgen; John K Orak; Inderjit Singh
Journal:  J Inflamm (Lond)       Date:  2010-04-19       Impact factor: 4.981

10.  SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology.

Authors:  Christian P Kamm; Heinrich P Mattle
Journal:  Trials       Date:  2009-12-14       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.